恩替卡韦联合扶正化瘀胶囊治疗HBeAg阳性失代偿期肝硬化患者的疗效分析
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases(2018)
Abstract
目的:探讨恩替卡韦联合扶正化瘀胶囊治疗HBeAg阳性失代偿期肝硬化患者的临床疗效.方法:选取HBeAg阳性失代偿期肝硬化患者138例,随机分为3组,每组46例.A组给予恩替卡韦治疗;B组给予恩替卡韦+复方鳖甲软肝片治疗;C组给予恩替卡韦+扶正化瘀胶囊治疗.观察3组患者治疗前后肝功能、肝纤维化指标变化及HBV DNA载量、HBV DNA转阴率及HBeAg转阴率.结果:3组患者治疗后肝功能、肝纤维化指标较治疗前好转;B、C两组患者治疗后ALT、AST、TBil、HA、LN、PCⅢ、CⅣ著低于A组治疗后,ALB高于A组治疗后;B、C两组患者门静脉内径、脾静脉内径、脾脏厚度较A组明显减少;B、C两组患者治疗后HBV DNA转阴率、HBe Ag转阴率显著高于A组治疗后;HBV DNA载量低于A组治疗后;差异均有统计学意义(P<0.05);B、C两组上述指标比较,差异无统计学意义(P>0.05).结论:恩替卡韦联合扶正化瘀胶囊治疗HBeAg阳性失代偿期肝硬化患者疗效确切,可以明显改善肝功能,有效抑制HBV复制.
MoreTranslated text
Key words
entecavir,fuzheng huayu capsule,decompensated cirrhotic.
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined